Showing 4 posts of 4 posts found.

Celgene completes Abraxis takeover

October 15, 2010
Research and Development, Sales and Marketing Abraxane, Abraxis, Celgene, mergers and acquisitions, oncology

Celgene has completed its acquisition of Abraxis BioScience for cash and stock totalling $2.9 billion. The takeover gives the cancer …

Manufacturing news in brief

November 30, 2009
Manufacturing and Production Abraxis, DSM, Hovione, Lonza

Pharmafocus’ round-up of developments in the pharmaceutical manufacturing sector includes new contracts for CMOs Lonza and DSM, facility news for …

Abraxis Biosciences launches Abraxane in Europe

January 2, 2009
Sales and Marketing Abraxis, Cancer, EU

US biotech company Abraxis BioScience has launched its innovative breast cancer treatment Abraxane in Europe. The drug is a variant …

College Hill to promote Abraxis ‘nanoparticle’ drug

December 10, 2008
Medical Communications Abraxis, College Hill

Abraxis Bioscience has appointed PR agency College Hill to promote its cancer drug Abraxane in Europe. The albumin-bound 'nano-particle' chemotherapeutic …

Latest content